Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study

Direct oral anticoagulants (DOACs) do not require concentration monitoring. However, whether DOAC concentrations are stable and their variation between and within patients is not well studied.

[1]  W. Lijfering,et al.  The relationship between DOAC levels and clinical outcomes: The measures tell the tale , 2020, Journal of thrombosis and haemostasis : JTH.

[2]  L. Visser,et al.  Body weight is negatively associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users , 2020, British journal of haematology.

[3]  Tanvi Patil,et al.  A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. , 2020, Thrombosis research.

[4]  H. Billett,et al.  Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. , 2019, The Lancet. Haematology.

[5]  H. Crijns,et al.  The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study , 2019, PloS one.

[6]  R. Testa,et al.  Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants , 2019, Journal of thrombosis and haemostasis : JTH.

[7]  M. Reichman,et al.  Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. , 2019, The American journal of medicine.

[8]  G. Lip,et al.  Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation , 2019, Expert opinion on drug metabolism & toxicology.

[9]  J. Thachil,et al.  The use of direct oral anticoagulants in chronic kidney disease , 2018, British journal of haematology.

[10]  R. Testa,et al.  Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants , 2018, Journal of thrombosis and haemostasis : JTH.

[11]  H. Büller,et al.  NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands , 2018, Thrombosis Journal.

[12]  S. Kitchen,et al.  International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants , 2018, Thrombosis and Haemostasis.

[13]  W. Ageno,et al.  Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians , 2018, Journal of thrombosis and haemostasis : JTH.

[14]  R. Arya,et al.  The impact of body weight on rivaroxaban pharmacokinetics , 2017, Research and practice in thrombosis and haemostasis.

[15]  Z. Goldberger,et al.  National Trends in Ambulatory Oral Anticoagulant Use. , 2015, The American journal of medicine.

[16]  E. Antman,et al.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.

[17]  J. Douketis,et al.  Real‐world variability in dabigatran levels in patients with atrial fibrillation , 2015, Journal of thrombosis and haemostasis : JTH.

[18]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[19]  D. van de Kerkhof,et al.  Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? , 2012, American journal of clinical pathology.

[20]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[21]  I. Abidin.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation , 2011 .

[22]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[23]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  W. Mueck,et al.  Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. , 2009, British journal of clinical pharmacology.

[25]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[26]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[27]  R. Abbate,et al.  Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. , 2016, Thrombosis research.

[28]  Paolo Prandoni,et al.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. , 2011, Clinical pharmacokinetics.

[29]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .